This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

We used stock screeners to make a list of biotech stocks under $20 and picked 8 stocks with the highest number of hedge fund ...

Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized oncology treatment over the last decade, offering targeted therapy options for several difficult cancers, espec ...

A single-center real-world study compares the effectiveness and toxicity of chimeric antigen receptor T-cell therapy vs ...

High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance ...

Study Highlights Dagger® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust ...

Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 ...

Mayo Clinic Comprehensive Cancer Center scientists, physicians and trainees will present nearly 60 studies on emerging cancer therapies, diagnostics and prevention strategies at the 2026 American ...

A personalized therapy involving re-engineered cells has brought phenomenal results for a woman with a rare trio of ...